Oncology
Sponsored
Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
News
Repligen builds in cell therapy with $1.5bn BioLife takeover
Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Oncology
Early diagnosis means little without timely treatment
Early diagnosis only changes outcomes if it is followed by timely treatment.
News
Celcuity gets FDA nod for first-in-class breast cancer drug
Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
